NC1153
| Code | Size | Price |
|---|
| TAR-T25855-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25855-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25855-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
NC1153 is a blocker of IL-2-induced activation of JAK3 and its downstream substrates STAT5a/b. It promotes long-term allograft survival and sparing the recipient from multiple toxicities.
CAS:
150661-91-9
Formula:
C18H36N2O
Molecular Weight:
296.499
Purity:
0.98
SMILES:
CN(C)CC1CCCCCCCCCC(CN(C)C)C1=O
References
1. Martinez GS, Ross JA, Kirken RA. Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors. Clin Cancer Drugs. 2016;3(2):131-137. doi: 10.2174/2212697X03666160610085943. PubMed PMID: 29046866; PubMed Central PMCID: PMC5642970.
2. Nagy ZS, Ross JA, Rodriguez G, Bader J, Dimmock J, Kirken RA. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways. FEBS Lett. 2010 Apr 16;584(8):1515-20. doi: 10.1016/j.febslet.2010.02.071. Epub 2010 Mar 6. PubMed PMID: 20211620; PubMed Central PMCID: PMC2854231.
3. Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, Kirken RA. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Mol Cancer. 2009 Aug 26;8:67. doi: 10.1186/1476-4598-8-67. PubMed PMID: 19709433; PubMed Central PMCID: PMC2741462.
4. Thompson JE. JAK protein kinase inhibitors. Drug News Perspect. 2005 Jun;18(5):305-10. Review. PubMed PMID: 16193102.